Skip to main content
HCPCS J3095 · Level II · Part B drug

J3095: telavancin (Vibativ), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J3095

Billing unit
10 MG
Telavancin injection
ASP payment limit
$8.149
October 2026; +8.9% vs July 2026
Practitioner MUE
150
MAI 3
OPPS status
SI K
APC 9258
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J3095 is the Level II code for Injection, telavancin, 10 mg, billed per 10 MG. The Medicare Part B ASP payment limit for October 2026 is $8.149 per billing unit, up 8.9% from July 2026. The practitioner MUE allows up to 150 units per date of service (MAI 3), so a full 150-unit day is $1,222.35 at the current limit. Under OPPS it carries status indicator K in APC 9258. The 10 mg billing unit means doses are reported in multiples of ten milligrams, with any remainder rounded per contractor policy; mismatched units against the NDC quantity trigger MUE and NDC-unit edits. The ASP crosswalk maps 2 NDCs to it, sold as Vibativ by Cumberland Pharmaceuticals Inc. No current Billing and Coding Article lists J3095, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J3095 at $8.149 per 10 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $7.484 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J3095
QuarterPayment limitPerCoinsurance
October 2026$8.14910 MG20%
July 2026$7.48410 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 2 NDCs from 1 labeler to J3095. Report the NDC in the claim's drug segment and bill the number of J3095 units that equals the quantity administered divided by 10 MG; the last column gives units per full package.

NDCs that crosswalk to J3095
NDCDrug nameLabelerPackage sizeBilling units / package
66220-0315-22VibativCumberland Pharmaceuticals Inc.1 × 12900
66220-0315-44VibativCumberland Pharmaceuticals Inc.1 × 4300

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J3095. For practitioners the limit is 150 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J3095 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services1503 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital1503 Date of Service Edit: ClinicalPrescribing Information
DME supplier03 Date of Service Edit: ClinicalCMS Policy

MUE for J3095 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J3095 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J3095 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J3095 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J3095 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J3095 carries status indicator K and is assigned to APC 9258, with a published national unadjusted payment of $8.149. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J3095 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $8.15 per 10 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for J3095 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J3095

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J3095

What does HCPCS code J3095 describe?

J3095 is defined by CMS as "Injection, telavancin, 10 mg". Each billing unit represents 10 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J3095 a CPT code?

No. J3095 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as telavancin (Vibativ); CPT codes are five-character codes maintained by the AMA. On a Part B claim J3095 reports the drug itself in 10 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J3095 in October 2026?

The ASP-based payment limit is $8.149 per 10 MG, with 20% beneficiary coinsurance. The July 2026 limit was $7.484. Commercial payers use their own fee schedules.

How many units of J3095 can be billed per day?

The practitioner Medically Unlikely Edit is 150 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to J3095?

The October 2026 ASP crosswalk lists 2 NDCs from 1 labeler: Vibativ (Cumberland Pharmaceuticals Inc.). For example NDC 66220-0315-22 (package size 1) equals 900 billing units of J3095.

Does J3095 have NCCI bundling edits?

No active practitioner PTP pairs list J3095 as a column-1 or column-2 code in the v323r0 release.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.